72 related articles for article (PubMed ID: 7468018)
1. [Kinetics and composition of cell populations in malignant astrocytomas].
Arkhangel'skiĭ VV; Kotel'nikov VM; Kachkov IA
Zh Vopr Neirokhir Im N N Burdenko; 1980; (6):3-7. PubMed ID: 7468018
[TBL] [Abstract][Full Text] [Related]
2. Changes of the bromodeoxyuridine labeling index of astrocytic tumors between primary and recurrent lesions.
Tamura M; Ono N; Zama A; Kurihara H
Noshuyo Byori; 1994; 11(2):173-6. PubMed ID: 7894621
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and immunohistochemical features of three pilomyxoid astrocytomas: comparative study with 11 pilocytic astrocytomas.
Amatya VJ; Akazawa R; Sumimoto Y; Takeshima Y; Inai K
Pathol Int; 2009 Feb; 59(2):80-5. PubMed ID: 19154260
[TBL] [Abstract][Full Text] [Related]
4. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
Lehnhardt FG; Bock C; Röhn G; Ernestus RI; Hoehn M
NMR Biomed; 2005 Oct; 18(6):371-82. PubMed ID: 15959923
[TBL] [Abstract][Full Text] [Related]
5. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
6. [Malignant astrocytoma and glioblastoma. Therapeutic results].
Rougier A; Pigneux J; Richaud P; Cohadon F
Sem Hop; 1983 Feb; 59(7):449-52. PubMed ID: 6302883
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Yamamoto M; Ikeda K; Ohshima K; Tsugu H; Kimura H; Tomonaga M
Cancer Res; 1997 Jul; 57(13):2799-805. PubMed ID: 9205092
[TBL] [Abstract][Full Text] [Related]
8. Development of anaplastic changes in low-grade astrocytomas of childhood.
Dirks PB; Jay V; Becker LE; Drake JM; Humphreys RP; Hoffman HJ; Rutka JT
Neurosurgery; 1994 Jan; 34(1):68-78. PubMed ID: 8121571
[TBL] [Abstract][Full Text] [Related]
9. [Various features of the proliferative activity of macroglial brain tumors in tissue culture].
Verkhogliadova TP; Semenova VM
Zh Vopr Neirokhir Im N N Burdenko; 1982; (5):36-41. PubMed ID: 7148254
[No Abstract] [Full Text] [Related]
10. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation of oligoastrocytoma: a case report.
Tsuboi Y; Kurimoto M; Nagai S; Kamiyama H; Endo S
Brain Tumor Pathol; 2007; 24(2):63-8. PubMed ID: 18095133
[TBL] [Abstract][Full Text] [Related]
13. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
Maris C; Rorive S; Sandras F; D'Haene N; Sadeghi N; Bièche I; Vidaud M; Decaestecker C; Salmon I
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):316-29. PubMed ID: 17983425
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology.
Scott IS; Morris LS; Rushbrook SM; Bird K; Vowler SL; Burnet NG; Coleman N
Neuropathol Appl Neurobiol; 2005 Oct; 31(5):455-66. PubMed ID: 16150117
[TBL] [Abstract][Full Text] [Related]
15. A2B5 lineages of human astrocytic tumors and their recurrence.
Xia CL; Du ZW; Liu ZY; Huang Q; Chan WY
Int J Oncol; 2003 Aug; 23(2):353-61. PubMed ID: 12851684
[TBL] [Abstract][Full Text] [Related]
16. Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.
Santi M; Mena H; Wong K; Koeller K; Olsen C; Rushing EJ
Cancer; 2003 Aug; 98(3):554-61. PubMed ID: 12879473
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas.
Chen B; Ahmed T; Mannancheril A; Gruber M; Benzil DL
Cancer; 2004 May; 100(10):2201-7. PubMed ID: 15139065
[TBL] [Abstract][Full Text] [Related]
19. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
[TBL] [Abstract][Full Text] [Related]
20. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
